Comparison between Zumsteg classification and Briganti nomogram for the risk of lymph-node invasion before radical prostatectomy
- 20 Downloads
To evaluate the performance of the Zumsteg classification to estimate the risk of lymph-node invasion (LNI) compared with the Briganti nomogram (BN) in prostatectomy patients with intermediate-risk prostate cancer (IRPC).
We included consecutive patients who had extended pelvic lymph-node dissection associated with radical prostatectomy for IRPC. To be classified favorable intermediate risk (FIR), patients could only have one intermediate-risk factor, fewer than 50% positive biopsies and no primary Gleason score of 4.
On the 387 patients included, 149 (38.5%) and 238 (54.3%) were classified FIR and unfavorable intermediate risk (UIR), respectively, and 212 (54.8%) had a BN inferior to 5%. Thirty-eight patients (9.8%) had LNI: 6 FIR patients (4.0%) versus 32 UIR patients (13.4%) and 14 patients (6.6%) with a BN inferior to 5% versus 24 patients (13.7%) with a BN superior to 5%. Eight patients with a BN inferior to 5%, but classified UIR, had LNI. Sensitivity to detect LNI was higher with the Zumsteg classification than with the BN: 84.2% (CI 95% [68–93]) versus 63.2% (CI 95% [46–78]). Both screening tests were concordant to predict LNI (kappa coefficient of 0.076, p < 0.05 for Zumsteg and Briganti)
Zumsteg classification appeared to be more sensitive and as effective (despite the impossibility to make decision curve analysis) than the BN to estimate the risk of LNI. Regarding the modest number of pN+ patients, further studies are needed to see the interest of proposing ePLND for UIR patients only.
KeywordsProstate cancer Intermediate risk Briganti nomogram Lymph-node invasion Zumsteg classification Radical prostatectomy
NB: protocol/project development, data collection or management, data analysis, and manuscript writing/editing; JW: protocol/project development and manuscript writing/editing; FL: data collection or management; YK: data collection or management; HT: protocol/project development; JTP: data collection or management; SG: data collection or management; MA: data analysis; DR: protocol/project development; GP: protocol/project development and manuscript writing/editing; CB: protocol/project development and manuscript writing/editing.
- 1.Mottet N, Bellmunt J, Bolla M et al (2019) EAU guidelines: EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Eur Assoc Urol 2017:146Google Scholar
- 6.Briganti A, Abdollah F, Nini A et al (2012) Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol 61:1132–1138. https://doi.org/10.1016/j.eururo.2011.11.008 CrossRefPubMedGoogle Scholar
- 10.Briganti A, Chun FK-H, Salonia A et al (2006) Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49:1019–1027. https://doi.org/10.1016/j.eururo.2006.01.043 CrossRefPubMedGoogle Scholar
- 11.Abdollah F, Cozzarini C, Sun M et al (2013) Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. Radiother Oncol 109:211–216. https://doi.org/10.1016/j.radonc.2013.05.029 CrossRefPubMedGoogle Scholar
- 12.Briganti A, Larcher A, Abdollah F et al (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61:480–487. https://doi.org/10.1016/j.eururo.2011.10.044 CrossRefPubMedGoogle Scholar
- 13.Dell’Oglio P, Abdollah F, Suardi N et al (2014) External validation of the european association of urology recommendations for pelvic lymph node dissection in patients treated with robot-assisted radical prostatectomy. J Endourol 28:416–423. https://doi.org/10.1089/end.2013.0571 CrossRefPubMedGoogle Scholar
- 15.Touijer KA, Ahallal Y, Guillonneau BD (2013) Indications for and anatomical extent of pelvic lymph node dissection for prostate cancer: practice patterns of uro-oncologists in North America. Urol Oncol Semin Orig Investig 31:1517–1521. https://doi.org/10.1016/j.urolonc.2012.04.021 CrossRefGoogle Scholar
- 17.Zumsteg ZS, Spratt DE, Pei I et al (2013) A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol 64:895–902. https://doi.org/10.1016/j.eururo.2013.03.033 CrossRefPubMedGoogle Scholar
- 25.Taira AV, Merrick GS, Galbreath RW et al (2010) Relationship between prostate cancer mortality and number of unfavourable risk factors in men treated with definitive brachytherapy: relationship between prostate cancer mortality and risk factors. BJU Int 106:809–814. https://doi.org/10.1111/j.1464-410X.2010.09269.x CrossRefPubMedGoogle Scholar
- 30.D’Amico AV, Whittington R, Malkowicz SB et al (2000) clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18:1164–1172. https://doi.org/10.1200/JCO.2000.18.6.1164 CrossRefPubMedGoogle Scholar
- 31.Briganti A, Capitanio U, Abdollah F et al (2012) Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool. Prostate 72:499–506. https://doi.org/10.1002/pros.21451 CrossRefPubMedGoogle Scholar
- 34.Evangelista L, Briganti A, Fanti S et al (2016) New clinical indications for 18F/11C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol 70:161–175. https://doi.org/10.1016/j.eururo.2016.01.029 CrossRefPubMedGoogle Scholar
- 36.Gandaglia G, Ploussard G, Valerio M et al (2019) A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies. Eur Urol 75:506–514. https://doi.org/10.1016/j.eururo.2018.10.012 CrossRefPubMedGoogle Scholar